Depot antipsychotic medications in bipolar disorder: A review of the literature

Acta Psychiatrica Scandinavica

Volumn 116, Issue SUPPL. 434, 2007, Pages 3-16

  Bond, D J ^a   Pratoomsri, W ^a   Yatham, L N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adherence; Bipolar disorder; Depot antipsychotics; Maintenance therapy

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE; PLACEBO; PROCYCLIDINE; QUETIAPINE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE; ZUCLOPENTHIXOL;

ACUTE DISEASE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FACE DISORDER; FACE MASKING; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INJECTION PAIN; INVOLUNTARY MOVEMENT; LONG TERM CARE; LOW DRUG DOSE; MANIA; MONOTHERAPY; PARKINSONISM; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 34547759790     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2007.01054.x     Document Type: Review

References (61)

1. Regier DA, Myers JK, Kramer M et al. The NIMH Epidemiologic Catchment Area (ECA) program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984 41 : 934 941.
2. Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1994 51 : 8 19.
3. Murray CJL, Lopez AD. Global and regional descriptive epidemiology of disability: incidence, prevalence, health expectancies and years lived with disability. In : Murray CLJ, Lopez AD, eds. The Global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA : Harvard University Press, 1996.
4. Lingham R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002 105 : 164 172.
5. Jamison KR, Gerner RH, Goodwin FK. Patient and physician attitudes toward lithium. Arch. Gen. Psych. 1979 36 : 866 869.
6. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996 153 : 993 1000.
7. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991 48 : 1082 1088.
8. Keck PE, McElroy SL, Strakowski SM et al. Factors associated with pharmacolic non-compliance in patients with mania. J Clin Psychiatry 1996 57 : 292 297.
9. Muller-Oerlinghausen B, Muser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J. Affective Disorders 1992 25 : 261 270.
10. Isometsa E, Henriksson M, Lonnqvist J. Completed suicide and recent lithium treatment. J. Affective Disorders 1992 26 : 101 104.
11. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003 64 (suppl. 16 34 40.
12. Tohen M, Zhang F, Taylor CC et al. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J. Affective Disorders 2001 65 : 85 93.
13. Tohen M, Sanger TM, McElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999 156 : 702 709.
14. Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania. Arch Gen Psychiatry 2000 57 : 841 849.
15. Tohen M, Baker RW, Altshuler LL et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002 159 : 1011 1017.
16. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002 63 : 1148 1155.
17. Tohen M, Goldberg JF, Gonzlaez-Pinto Arrillaga AM et al. A 12-week, double-blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003 60 : 1218 1226.
18. Vieta E, Calabrese JR, Hennen J et al. Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J Clin Psychiatry 2004 65 : 1420 1428.
19. Tohen M, Chengappa KNR, Suppes T et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002 59 : 62 69.
20. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. Arch Gen Psychiatry 2003 60 : 1079 1088.
21. Tohen M, Chengappa KNR, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer vs. mood stabilizer alone. British J. Psychiatry 2004 184 : 337 345.
22. Tohen M, Ketter TA, Zarate CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47 week study. Am J Psychiatry 2003 160 : 1263 1271.
23. Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005 162 : 1281 1290.
24. Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006 163 : 247 256.
25. Hirschfeld RMA, Keck PE, Kramer M et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004 161 : 1057 1065.
26. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilizers plus risperidone or placebo in the treatment of acute mania. British J. Psychiatry 2002 182 : 141 147.
27. Sachs G, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for the treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002 159 : 1146 1154.
28. Bowden CL, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005 66 : 111 121.
29. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomized, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005 15 : 573 585.
30. Yatham LN, Paulsson B, Mullen J, Vagero M. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004 24 : 599 606.
31. Sachs G, Chengappa KNR, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disorders 2004 6 : 213 223.
32. Calabrese JR, Keck PE, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005 162 : 1351 1360.
33. Keck PE, Versiani M, Potkin S et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controleld, double-blind randomized trial. Am J Psychiatry 2003 160 : 741 748.
34. Keck PE, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003 160 : 1651 1658.
35. Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005 7 (suppl. 3 5 69.
36. Lowe MR. Treatment of rapid cycling affective illness. British J. Psychiatry 1985 146 : 558.
37. Naylor GJ, Scott CR. Depot injections for affective disorders. British J. Psychiatry 1980 136 : 150.
38. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993 8 : 119 122.
39. Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. British J. Psychiatry 1994 165 : 827 829.
40. Lowe MR, Batchelor DH. Depot neuroleptics and manic-depressive psychosis. Int Clin Psychopharmacol 1986 1 (Suppl. 1 53 62.
41. Ahlfors UG, Baastrup PC, Dencker SJ et al. Flupenthixol decanoate in recurrent manic-depressive illness: a comparison with lithium. Acta Psychiatr Scand 1981 64 : 226 237.
42. Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE. Comparison of the prophylactic action of flupenthixol with placebo in lithium-treated manic depressive patients. British J. Psychiatry 1986 148 : 723 725.
43. Kielholz P, Terzani S, Poldinger W. The long-term treatment of periodical and cyclic depressions with flupenthixol decanoate. Int. Pharmacopsychiatry 1979 14 : 305 309.
44. Savas HA, Yumru M, Ozen ME. Use of long-acting risperidone in the treatment of bipolar patients. J. Clin. Psychopharm. 2006 5 : 530 531.
45. Han C, Lee M-S, Pae C-U, Ko Y-H, Patkar AA, Jung I-K. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog. Neuropsychopharm. Biol. Psychiatry 2007 doi:.
46. Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. Int. J. Psychopharmacol. (in press).
47. Medori R, Braunig P, Sacchetti E. Bipolar disorder: 6-months efficacy of risperidone injectable. World J. Biol. Psychiatry 2005 6 (Suppl. 1 192 193.
48. Bain E, Gharabawi G, Locklear J, Turkoz I, Yurgelin-Todd D. A study of long-acting, injectable risperidone in frequently relapsing bipolar disorder (FRBD): preliminary findings. Presented at the 44th Annual Meeting of the American College of Neuropsychopharmacology; December 11-15, 2005 Waikoloa, Hawaii.
49. Yatham L, Binder C, Fallu A. Randomized trial of oral vs. injectable antipsychotics in bipolar disorder. Presented at the 6th International Conference on Bipolar Disorder; June 16-18, 2005 Pittsburgh, PA.
50. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors. Arch Gen Psychiatry 1982 39 : 473 481.
51. Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 1984 25 : 135 138.
52. Morgan HG. The incidence of depressive symptoms during recovery from hypomania. British J. Psychiatry 1972 120 : 537 539.
53. Zarate CA, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004 161 : 169 171.
54. Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA. Efficacy and safety of long-acting ripseridone in sdtable patients with schizoaffective disorder. J. Affective Disorders 2004 83 : 263 275.
55. Mohl A, Westlye K, Opjordsmoen S et al. Long-acting risperidone in stable patients with schizoaffective disorder. J. Psychopharm. 2005 19 (Suppl. 1 22 31.
56. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. European Psychiatry 2004 19 : 219 225.
57. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British J. Psychiatry 2001 179 : 290 299.
58. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002 59 : 530 537.
59. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003 60 : 261 269.
60. Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv 2004 55 : 264 269.
61. Keller MB. Improving the course of illness and promoting continuation of treatment of bipolar disorder. J Clin Psychiatry 2004 65 (Suppl. 15 10 14.